

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/010,055	11/09/2001	Benjamin R. Yerxa	03678.0023.CNUS04	8525	
27194	7194 7590 03/17/2004		EXAMINER		
HOWREY SIMON ARNOLD & WHITE, LLP BOX 34 301 RAVENSWOOD AVE. MENLO PARK, CA 94025			LEWIS, PA	LEWIS, PATRICK T	
			ART UNIT	PAPER NUMBER	
			1623		
			DATE MAILED: 03/17/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		-				
	Application No.	Applicant(s)				
	10/010,055	YERXA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Patrick T. Lewis	1623				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timed within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>18 December 2003</u> .						
	<u> </u>					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-11</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-11</u> is/are rejected.						
7) Claim(s) is/are objected to.						
	8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10)⊠ The drawing(s) filed on <u>09 November 2001</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	•	·				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>09042003</u>. 	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite atent Application (PTO-152)				

Application/Control Number: 10/010,055

Art Unit: 1623

DETAILED ACTION

Election/Restrictions

- 1. Applicant's election without traverse of Group II wherein **X** is oxygen, **m** + **n** = 2, and **B** and **B'** are a pyrimidine of general Formula **IIb** in Paper No. 4 dated July 8, 2003 is acknowledged. Election was made **without** traverse.
- 2. The restriction requirement as to the encompassed species is hereby withdrawn and claims directed to the species drawn to the variables **X**, **m** + **n**, and **B** and **B**' are no longer withdrawn from consideration since all of the claims to this species depend from or otherwise include each of the limitations of an allowed generic claim.

In view of the above noted withdrawal of the restriction requirement as to the linked species, applicant(s) are advised that if any claim(s) depending from or including all the limitations of the allowable generic linking claim(s) be presented in a continuation or divisional application, such claims may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Applicant's Response dated December 18, 2003

3. In the Response filed December 18, 2003, claims 1-11 were amended and claim 12 was canceled. Applicant presented arguments directed to the rejection of claims 1-

Application/Control Number: 10/010,055

Art Unit: 1623

5, 8, and 10-11 under 35 U.S.C. 112, second paragraph, and the rejection of claims 1-11 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-9 of prior U.S. Patent No. 5,900,407.

- 4. Claims 1-11 are pending. An action on the merits of claims 1-11 is contained herein below.
- 5. The rejection of claims 1-5, 8, and 10-11 under 35 U.S.C. 112, second paragraph, has been render moot in view of applicant's amendment/arguments dated December 18, 2003.
- 6. The rejection of claims 1-11 under 35 U.S.C. 101 as claiming the same invention as that of claims 1-9 of prior U.S. Patent No. 5,900,407 has been rendered moot in view of applicant's amendments dated December 18, 2003.

Claim Rejections - 35 USC § 112

- 7. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 8. Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Variables R_1 and R_2 of Formula IIa have not been defined by the claims.

Double Patenting

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

Application/Control Number: 10/010,055

Art Unit: 1623

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 1-11 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 5,900,407. Although the conflicting claims are not identical, they are not patentably distinct from each other.

The difference between the instantly claimed method of stimulating tear secretion and mucin production and the method of stimulating tear secretion of the '407 patent is that the method of the '407 patent is not limited to the use of the dinucleotide of Formula II. The claims of '407 and the instant invention overlap substantially, and to issue a patent to the claims of the instant application would be to extend the patent term for subject matter patented in '407.

11. Claims 1-11 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2, 4, and 7-15 of copending Application No. 10/041,826. Although the conflicting claims are not identical, they are not patentably distinct from each other.

Art Unit: 1623

The difference between the instantly method and the method of the '826 application is that the '826 application is drawn to a method of enhancing drainage of the lacrimal system; however one of ordinary skill in the art at the time of the invention would have a reasonable expectation of success of enhancing drainage of the lacrimal system employing the method of the instant application since both methods employ the same nucleotide (compound of Formula II) and methodological steps (administration of a compound of Formula II to the eyes). Likewise, one of ordinary skill in the art at the time of the invention would have a reasonable expectation of success in employing the method of the '826 to stimulate tear secretion and mucin production in the eye. Although the two inventions are drawn to a different effect, they are not patentably distinct.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

12. Claims 1-11 are pending. Claims 1-11 are rejected. No claims are allowed.

Contacts

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick T. Lewis whose telephone number is 571-272-0655. The examiner can normally be reached on M-F 10:00 am to 3:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patrick T. Lewis, PhD Examiner Art Unit 1623 James O. Wilson

Supervisory Patent Examiner
Lechnology Center 1600

ptl

March 15, 2004